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ABSTRACT
The receptor tyrosine kinase AXL promotes migration, invasion, and metastasis. 
Here, we evaluated the role of AXL in endometrial cancer. High immunohistochemical 
expression of AXL was found in 76% (63/83) of advanced-stage, and 77% (82/107) 
of high-grade specimens and correlated with worse survival in uterine serous cancer 
patients. In vitro, genetic silencing of AXL inhibited migration and invasion but had no 
effect on proliferation of ARK1 endometrial cancer cells. AXL-deficient cells showed 
significantly decreased expression of phospho-AKT as well as uPA, MMP-1, MMP-2, 
MMP-3, and MMP-9. In a xenograft model of human uterine serous carcinoma with 
AXL-deficient ARK1 cells, there was significantly less tumor burden than xenografts 
with control ARK1 cells. Together, these findings underscore the therapeutic potentials 
of AXL as a candidate target for treatment of metastatic endometrial cancer.
INTRODUCTION
Endometrial cancer (EC) is the most common 
gynecologic malignancy in the United States with 60,050 new 
cases and 10,470 disease-related deaths projected for 2016. 
The prognosis for early-stage cancer has a five-year survival 
rate of 80% to 95% [1, 2]. However, about 29% of patients are 
diagnosed with aggressive tumors that have spread to regional 
lymph nodes or metastasized to more distant areas [1]. In 
patients with distant EC, the five-year survival rate is only 
17% [1]. The more aggressive variant of type II EC, uterine 
serous cancer, accounts for only 10% of all EC cases but is 
responsible for 40% of deaths by this disease [3, 4]. Currently, 
the standard treatment for EC consists of surgery followed 
by hormonal therapy, chemotherapy, and/or radiation 
therapy, depending on patient age and comorbidities, tumor 
stage and grade, performance status, and prior treatments 
[5]. Although chemotherapy is the treatment of choice for 
metastatic or recurrent EC, median survival is only about 12 
months for these patients [6-8]. High mortality and limited 
treatment options underscore the challenge of metastatic 
disease. Developing effective treatments will require a better 
understanding of EC metastasis and identification of more 
effective therapeutic targets.
The receptor tyrosine kinase AXL has been identified 
as a novel therapeutic target given its involvement in tumor 
invasion and migration. As a member of the TAM family 
of receptor tyrosine kinases, AXL contains an extracellular 
domain composed of two immunoglobulin-like domains and 
two fibronectin type III domains [9, 10]. The extracellular 
domain resembles that of adhesion molecules, and 
overexpression of AXL causes an adhesive phenotype [11, 
12]. Binding of growth arrest specific gene-6 (GAS-6), the 
only known ligand for AXL, induces autophosphorylation 
of tyrosine residues 779, 821, and 866 [13-15]. Activation 
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of AXL stimulates several signal transduction pathways, 
including MAPK/ERK kinases, PI3K/AKT, NF-κB, and 
STAT and promotes proliferation, anti-apoptosis, survival, 
cellular migration, invasion, adhesion, and pro-inflammatory 
cytokine production [14, 16-21].
AXL is overexpressed or ectopically expressed in 
multiple cancers including breast, prostate, ovarian, and 
endometrial cancer [10, 22-29]. In tumor cells, AXL over-
expression promotes migration and invasion, whereas 
AXL inhibition decreases cell invasion and increases 
chemosensitivity [29-31]. In vivo, AXL signaling 
promotes metastasis in breast, glioma, lung, and ovarian 
cancer [24, 32-36]. These findings demonstrate that AXL 
is an important driver of tumor metastasis.
AXL overexpression has been reported in human 
uterine cancer [27], but the role of AXL in EC progression 
has yet to be elucidated. Using both in vitro and in vivo 
approaches, we demonstrate that AXL is critical in EC 
invasion, migration, and metastasis. Thus, our study 
supports the therapeutic potential of targeting AXL to 
inhibit metastatic EC.
RESULTS
AXL is upregulated in endometrial cancer tissues
To confirm and extend previous reports of AXL 
overexpression in human EC samples, we performed 
immunohistochemical analysis of human endometrial 
tissue microarrays that included benign endometrial 
glands, endometrioid cancer, serous adenocarcinoma, and 
several other mixed cancer types and metastases (Table 1 
and Figure 1A). Tissues were scored on a 0–3 scale by 
the percentage of AXL-positive cells. Our data show that 
whereas 24% (15/63) of normal specimens expressed high 
levels of AXL (score 2, or 3), 63% (180/287) of primary 
type I and type II endometrial carcinoma samples and 86% 
(286/332) of endometrial cancer in all stages (primary 
tumors and metastases) expressed AXL (P<0.0001 
for both, Table 1). Therefore, AXL was more highly 
expressed in malignant endometrium than in normal 
endometrium. Additionally, tumor samples collected from 
metastatic sites showed significantly higher expression 
of AXL than normal samples; whereas 85% (11/13) of 
metastatic carcinoma samples expressed AXL and 46% 
(6/13) received a score of 3, only 43% (27/63) of normal 
samples expressed AXL and only 5% (3/63) received a 
score of 3 (P=0.0001, Table 1). Advanced-stage and 
high-grade endometrial carcinomas also expressed more 
AXL than early-stage and low-grade carcinomas. For 
example, 19% of stage I carcinomas received an AXL 
score of 3, versus 51% of stage III and 38% of stage IV 
carcinomas (P=0.0003, Table 1). Similarly, only 14% of 
grade 1 carcinomas were scored as 3 versus 45% of grade 
3 carcinomas (P<0.0001, Table 1). These results indicate 
that AXL expression was significantly elevated in primary 
endometrial cancer tumors, especially in higher-grade and 
advanced stage tumors and metastatic sites.
In a subset of 20 patients for whom we had clinico-
pathological and survival information, 8 patients with low 
AXL expression had longer median survival (96 months) 
than the 12 patients with high AXL expression (96 vs. 56 
months, P= 0.0285, Figure 1B).
AXL promotes invasion and migration of 
endometrial cancer cells
To define the role of AXL in endometrial cancer, 
we first screened five EC cell lines for AXL expression. 
AXL was abundantly expressed in two cell lines 
derived from type II metastatic EC, ARK1 and Hec50a 
(Figure 2A). In contrast, AXL was expressed at very low 
levels in AN3CA (derived from a grade 3 endometrioid 
adenocarcinoma), KLE (derived from a poorly 
differentiated adenocarcinoma), and Ishikawa (derived 
from a well differentiated type I adenocarcinoma) cells 
(Figure 2A).
To examine the role of AXL in proliferation of 
EC cells, we used short hairpin RNAs (shRNAs) to 
generate AXL-deficient metastatic endometrial cancer 
cell lines (ARK 1 and Hec50a) as described previously 
[37] and confirmed AXL knockdown by Western analyses 
(Figure 2B). We then used an XTT-based assay to measure 
proliferation of ARK1 cells containing scrambled shRNA 
(shSCRM) or AXL-targeting shRNA (shAXL). Over a 
period of 4 days, we found no significant difference in 
cellular growth curves (Figure 2D). Consistent with this 
finding, we examined ARK1 cells transfected with small 
interfering RNA (siAXL or siControl, Figure 2C) and 
found no difference in growth curves (Figure 2E). Thus, 
we conclude that AXL is not necessary for endometrial 
cancer cell proliferation in vitro.
To evaluate the contribution of AXL to tumor cell 
invasion, we performed matrigel invasion assays and 
found that AXL-deficient ARK 1 and Hec50a cells were 
significantly less invasive than controls (Figure 3A). 
ARK1 cells transfected with AXL siRNA were similarly 
inhibited in their invasive ability (Supplementary 
Figure S1A). Likewise, shAXL ARK1 and Hec50a and 
siAXL ARK1 cells were less able to migrate in a transwell 
assay than the respective control cells (Figure 3B and 
Supplementary Figure S1B).
We further examined the effects of therapeutic 
inhibition of AXL using a small molecule inhibitor 
R428[34]. We first confirmed the effectiveness of R428 
in inhibiting p-AXL expression after stimulation with 
GAS6 (Supplementary Figure S2A). We then found 
that pre-treatment of ARK1 with R428 for four hours 
inhibited invasion (Supplementary Figure S2B). Thus, 
our data shows that AXL plays an important role in 
invasion and migration of uterine serous cancer cells 
and that its inhibition would significantly hinder these 
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processes. We next sought to determine the molecular 
mechanism by which AXL regulates EC cell invasion and 
migration. We were particularly interested in the PI3K/
AKT pathway because AXL has been reported to regulate 
ovarian cancer metastasis through this pathway [24]. To 
determine whether PI3K/AKT signaling is affected by loss 
of AXL in endometrial cancer cells, we performed Western 
blot analyses evaluating levels of AKT phosphorylated 
at Ser473 (P-AKT) on shSCRM and shAXL ARK1 
and Hec50a cells. Protein expression on western blot 
confirmed that AXL-deficient ARK1 and Hec50a cells 
have significantly reduced P-AKT and GAS6 expression 
than the shSCRM counterpart (Figure 4A).
To determine whether AXL activation in uterine 
cancer is ligand dependent, we starved ARK1 and 
Hec50a cells for 48 hours. Then exogenous GAS6 was 
added at 600ng/ml concentration for 15mins to stimulate 
AXL activation. Western blot analysis showed that 
exogenous GAS6 induced phosphorylation of AXL in both 
endometrial cancer cell lines (Figure 4B).
To examine components downstream of PI3K/
AKT pathway, we focused on matrix metalloproteinases 
(MMPs) because they have been found to be major 
contributors to tumor cell invasion and metastasis [38-40]. 
Expression of MMP-1 and MMP-2 has been reported to 
be associated with EC cell invasion [41, 42]. Additionally, 
AXL has been shown to regulate MMP-1, MMP-2 and 
MMP-9 expression in ovarian cancer [24]. Likewise, 
MMP-3 has been associated with vascular invasion in EC 
and AXL has been reported to induce MMP-3 expression 
in head and neck cancer cell invasion [43, 44]. We also 
examined expression of urokinase-type plasminogen 
activator (uPA) since it has also been reported to enhance 
EC cell invasion via phosphorylation of AKT [45]. 
We found that AXL-deficient ARK1 cells expressed 
significantly less MMP-1, MMP-2, MMP-9, and uPA than 
controls (Figure 4C). Similarly, AXL-deficient Hec50a 
cells expressed significantly less MMP-1, MMP-2, MMP-
3, and uPA than control cells (Figure 4C). To assess 
functional measures, gelatin zymogram for MMP-2 and 
Table 1: AXL expression in human endometrial cancer.
Immunohistochemical analysis of AXL staining in normal endometrial glands, human endometrial tumors and metastases.
Analysis of AXL Staining to Endometrial Tumor Parameters
Score 0 1 2 3 Total
Benign/Atrophic Endometrium 36 (57) 12 (19) 12 (19) 3 (5) 63
Type I
  Endometrioid 46 (18) 51 (19) 67 (26) 96 (37) 260
Type II
  Serous 2 (8) 5 (21) 6 (25) 11 (46) 24
  Clear-Cell 2 (67) 1 (33) 0 0 3
Mixed 1 (5) 5 (23) 8 (36) 8 (36) 22
Stromal Sarcoma 1 (25) 3 (75) 0 0 4
Carcinosarcoma 0 2 (25) 2 (25) 4 (50) 8
Metastatic Carcinoma 2 (15) 3(23) 2(15) 6(46) 13
Stagea
  I 35 (16) 37 (18) 99 (47) 41 (19) 212
  II 5 (14) 7 (19) 12 (32) 13 (35) 37
  III 6 (8) 10 (13) 21 (28) 38 (51) 75
  IV 2 (25) 2 (25) 1 (12) 3 (38) 8
Grade
  1 20 (35) 10 (17) 20 (34) 8 (14) 58
  2 12 (12) 16 (16) 39 (38) 34 (34) 101
  3 10 (9) 15 (14) 34 (32) 48 (45) 107
Values are presented as n (%). AXL staining score: 0, 0% AXL-expressing cells; 1, 1%–19%; 2, 20%–59%; 3, >60%. a Of 
the 334 total specimens, stage was available for 332 of these specimens.
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MMP-9 was performed on Hec50a and ARK1 shSCRM 
and shAXL cells. Hec50a shAXL showed significantly 
less active MMP-2 and MMP-9, and ARK1 shAXL had 
less active MMP-2 than shSCRM cells (Figure 4D). Taken 
together, our results suggest that AXL regulates MMPs 
and uPA expression through the PI3K/AKT pathway in 
EC cells.
Genetic inhibition of AXL significantly reduces 
endometrial cancer metastasis in mice
Finally, we sought to examine the role of AXL in 
EC metastasis in vivo. Since advanced-stage EC presents 
with intraperitoneal metastasis, we used a mouse model 
in which NOD-SCID mice are intraperitoneally injected 
with ARK1 cells. In this model, mice develop ascites 
and many small metastatic lesions attached to the 
mesentery, omentum, and other peritoneal surfaces [46]. 
We intraperitoneally injected mice with luciferase labeled 
ARK1 cells either shAXL or shSCRM. After 35 days, 
we performed in vivo evaluation using bioluminescence 
imaging (BLI) to ensure tumor growth and metastases 
development in the injected mice. BLI quantification 
highlighted the difference in the ability of shSCRM and 
shAXL ARK 1 to form metastases. Specifically, ARK1 
shSCRM had significantly higher mean BLI intensity 
(5.9x108±1.7x108) than those injected with ARK1 shAXL 
cells (5.1x107±1.1x107), indicating higher tumor burden 
(P=0.0085, Figure 5A). After 60 days, we counted and 
weighed the tumors. Mice injected with AXL-deficient 
cells developed fewer intraperitoneal metastases and 
had lower tumor weight than mice injected with AXL-
expressing cells (Figure 5B, 5C and 5D). The average 
number of peritoneal metastases was significantly reduced 
from 47±8 in shSCRM injected mice to 9 ±2 in shAXL 
injected mice (P<0.0001, Figure 5B). Likewise, the 
average tumor weight was reduced greatly from 598 ± 
63mg in shSCRM injected mice to 281 ± 29mg in shAXL 
Figure 1: High AXL expression in endometrial tumors correlates with lower survival. A. Representative images of AXL 
immunohistochemical staining in benign endometrial glands, high grade endometrioid, and serous carcinomas at 20X magnification. 
B. Kaplan-Meier curves showing differences in survival between low AXL and high AXL expressing uterine serous tumors. Tumors 
expressing low AXL (5-10%, n=8) have survival median of 96 months while tumors expressing high AXL (60-100%, n=12) have 
significantly lowered survival of 56 months (P=0.0285).
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Figure 2: Genetic inactivation of AXL does not affect proliferation of endometrial cancer cell line. A. Western blot analysis 
of AXL (140 kDa) and GAS6 (75kDa) expression in a panel of human endometrial cancer cell lines. Vinculin (125 kDA) is shown as a 
loading control. B. Western blot analysis of AXL (140 kDa) expression in ARK1 and Hec50a cells stably transfected with shRNA targeting 
AXL (shAXL) or scramble control (shSCRM). Heat shock protein 70 (Hsp70, 70 kDa) is shown as a protein loading control. C. Western 
blot analysis of AXL (140 kDa) and GAS6 (75kDa) expression in siControl and siAXL ARK1 cells at 72, 96, 120, and 144 hours post 
transfection. β-actin (42 kDa) is shown as a loading control. D. Cellular growth curves for ARK1 shSCRM and shAXL cells (n=3). Data are 
represented as mean +/- SEM. E. Cellular growth curves for siControl and siAXL ARK1 cells (n=3). Cells were plated into 96 wells plate 
for XTT proliferation assay 48hrs after siRNA transfection. Data are represented as mean +/- SEM.
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Figure 3: AXL is essential to invasion and migration of endometrial cancer cells. A. Matrigel invasion assay of ARK1 
and Hec50a shSCRM and shAXL cells. Images were taken after 48h at 20X magnification showing fewer invading cells for AXL 
deficient cells. Graphs show quantification of invasion assays (n=3). Data are represented as mean +/- SEM and asterisks indicate 
a significant increase or decrease in expression compared with shSCRM as determined by student’s t test (**, P < 0.01; ***, P < 
0.001). B. Migration assay using boyden chambers of shSCRM and shAXL ARK1 and Hec50a cells. Images were taken after 48h at 
20X magnification illustrating inhibition of shAXL cell migration. Graphs show quantification of migration assays (n=3). Data are 
represented as mean +/- SEM and asterisks indicating statistical significance compared to shSCRM as determined by the student’s 
t-test (***, P < 0.001; ****, P <0.0001).
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Figure 4: AXL regulates PI3K/AKT signaling pathway and MMP expression in endometrial cancer cells. A. Western blot 
analysis of phospho-AKT (Ser473, 56-60 kDa), total AKT (60 kDa), AXL (140 kDa), and GAS6 (75 kDa) expression in ARK1 and Hec50a 
cells expressing shSCRM or shAXL. β-actin (42 kDa) is shown as a loading control. B. Western blot analysis of AXL (140 kDa), phospho-
AXL (Tyr702, 140 kDa) and GAS6 (75 kDa) expression in starved ARK1 and Hec50a cells with or without GAS6 stimulation. β-actin 
(42 kDa) is shown as a loading control. C. Real time PCR analysis of MMP-1,-2,-3,-9, uPA, and AXL expression in shAXL and shSCRM 
endometrial cancer ARK1 and Hec50a cells. Expression values were normalized to 18S and fold changes were calculated over shSCRM 
(n=3). Data are represented as mean +/- SEM and asterisks indicate significant increase or decrease in expression compared to shSCRM as 
determined by the student’s t-test (**, P < 0.01; ***, P < 0.001; ****, P <0.0001). D. Gelatin zymography assay for pro- and active-MMP2 
and MMP-9 activity in conditioned media collected from serum starved Hec50a cells.
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Figure 5: Genetic inactivation of AXL significantly inhibits endometrial metastasis in mouse model. A. Bioluminescent 
imaging (BLI) of mice injected with luciferase-tagged ARK1 shSCRM and shAXL cells at 35 days following injection. Graph on the right 
shows quantification of BLI intensity. Data are represented as mean +/- SEM and asterisks indicating statistical significance as determined 
by the student’s t-test (**, P < 0.01). B. Representative images of abdominal cavity taken ~60 days after injection with shSCRM and shAXL 
ARK1 cells. Note that mice injected with shSCRM cells visually displayed more tumor metastasis throughout the abdominal cavity than 
shAXL mice (circled). Graphs depict the average number of all peritoneal metastases >1mm in size per mouse and the average weight of 
total tumor nodules from each treatment group (n=9 per group). Data are represented as mean +/- SEM and asterisks depict significant 
change in tumor burden as determined by student’s t test (****, P < 0.0001). C. Images of the mesentery from mice injected with shSCRM 
or shAXL ARK1 cells. Note that tumor nodules are circled. Graphs on the right depict average number of tumor nodules and tumor weight 
from the mesentery alone. Data are represented as mean +/- SEM and asterisks depict significant change in tumor burden as determined by 
student’s t test (**, P < 0.01; ***, P < 0.001). D. Images of the omentum from mice injected with shSCRM or shAXL ARK1 cells. Graphs 
on the right depict average number of tumor nodules and tumor weight from the omentum alone. Data are represented as mean +/- SEM and 
asterisks depict significant change in tumor burden as determined by student’s t test (***, P < 0.001; ****, P < 0.0001).
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injected mice (Figure 5B, P< 0.0001). We observed 
similar reductions in tumor number and weight when the 
tumors were divided according to the site of metastasis, 
either in the mesentery or omentum (Figure 5C and 5D). 
Overall, these findings demonstrate that knockdown of 
AXL expression in ARK 1 cells inhibited endometrial 
cancer metastasis. This is the first in vivo experiment to 
establish the essential role of AXL in the development of 
EC metastasis.
We further evaluated whether tumors seen in 
the shAXL model expressed AXL, and we found that 
a portion of tumors that grew either had AXL protein 
expression or a lack of AXL expression. Therefore 
tumor growth was due to either incomplete knockdown 
or growth despite knockdown (Supplementary Figure 
S3A). At the mRNA level, AXL knockdown tumors were 
found to have low expression of AXL (Supplementary 
Figure S3B). In addition, shAXL tumors had less p-AKT 
protein expression, uPA, MMP-1, MMP-2, MMP-3 and 
MMP-9 mRNA expression as seen in vitro. To further 
confirm whether AXL regulates metastasis rather than 
proliferation, Ki67 expression was evaluated in the 
xenograft tumors and shAXL tumors had similar Ki67 
expression as shSCRM (Supplementary Figure S4). This is 
consistent with our findings that AXL inhibition decreases 
tumor growth via inhibition of metastasis rather than by 
proliferation.
DISCUSSION
Metastatic and recurrent EC pose challenges to 
current therapies as median patient survival is less than 
one year [6-8]. Moreover, current chemotherapies for 
advanced EC can result in significant morbidity, leading 
to poor tolerability and ultimately discontinuation in some 
cases [47]. However, advances in the understanding of 
the molecular mechanisms underlying cancer have made 
it possible to use targeted agents to disrupt cancer cell 
progression and survival. This targeted approach may be 
able to reduce systemic side effects and improve quality of 
life and overall survival for patients [47, 48].
To date, there are few receptor tyrosine kinases that 
have been identified as major factors in EC invasion. More 
specifically, the biological role of AXL, a receptor tyrosine 
kinase, in EC remains largely uncharacterized despite its 
promising advances in numerous cancers. In this study, 
we confirmed that AXL was significantly upregulated in 
EC tissues and correlated with advanced stage and worse 
survival. Our sample size for the survival analysis was 
limited to 8 patients for the low expression AXL group and 
12 for the high AXL expression group, and other confounding 
factors such as age, chemoresistance, and other pathology 
risk factors were unavailable for analysis. Future studies are 
needed to confirm these findings. Nonetheless, this is the 
first data to implicate AXL as a clinically relevant prognostic 
factor in EC, in particular, associated with worse prognosis.
Furthermore, we demonstrated that genetic 
knockdown of AXL significantly inhibited EC invasion 
and metastasis both in vitro and in vivo. Pharmacological 
inhibition using R428 was also used to inhibit endometrial 
cancer cell invasion in vitro, suggesting clinical relevance 
of AXL inhibition. As in ovarian cancer, reduction of AXL 
expression primarily reduced the establishment of new 
metastatic lesions during progression of EC metastasis 
rather than reducing proliferation of the established 
tumors themselves [24]. Immunohistochemical analysis 
of Ki-67 expression in ARK1 shAXL and shSCRM 
mouse xenografts confirms that AXL knockdown has no 
significant effect on Ki-67. This is consistent with our 
proliferation data in which AXL displayed no effect on 
the proliferation and growth of ARK1 cells. AXL has been 
shown to regulate proliferation and survival in a number 
of cancers; however, it appears that AXL signaling and 
overall biological effect differs depending on tumor type. 
This study provides more support that AXL may inhibit 
invasion but not proliferation as seen in ovarian cancer 
[24]. Although the majority of anti-cancer agents are 
directed at growth inhibition, most cancer patients are 
affected by metastasis [49]. Few drugs have been proven 
effective at treating cancer metastasis [49]. Our data 
suggests AXL to be a promising candidate for inhibiting 
EC metastasis.
We have demonstrated ligand-dependent activation 
of AXL in EC. Starved ARK1 cells had low levels of 
endogenous GAS6 and minimal p-AXL. Upon stimulation 
with exogenous GAS6, AXL phosphorylation was 
induced. Additionally, GAS6 levels correlated with AXL 
expression in EC cell lines as well as a decreased level 
in cells with genetic inactivation of AXL. Thus indicating 
GAS6 to be an important factor to consider with AXL 
inhibition. We also showed that AXL regulation of EC 
is likely through the PI3K/AKT pathway. Given the 
importance of the PI3K/AKT pathway in gynecologic 
carcinogenesis, our findings suggest that AXL might be a 
novel target to inhibit upstream of this pathway. Moreover, 
we demonstrated that silencing AXL significantly 
inhibited the expression of proteins involved in the 
regulation of the extracellular matrix such as MMPs and 
uPA, unveiling the pathway by which AXL mediates 
tumor metastasis. Urokinase-type plasminogen activator 
(uPA), an important player in the degradation of the 
extracellular matrix, is associated with worse prognosis in 
EC [45, 50]. Furthermore, uPA has been reported to boost 
EC cell invasion via increased levels of p-AKT, p-ERK1/2 
and p-p38 [45]. This is the first time that uPA has been 
shown to be regulated by AXL, possibly through the 
p-AKT pathway. This finding illuminates a more complete 
mechanism by which AXL and its downstream proteins 
interact to enhance cancer invasion.
Overall, current molecular-targeted agents against 
EC exhibited low impact on survival and response in 
clinical trials, suggesting that further studies are needed 
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to address the problems with current agents and identify 
more effective molecular targets [47]. Taken together, our 
data suggest that AXL may be a novel therapeutic target 
to inhibit endometrial cancer metastasis. In fact, AXL-
specific inhibitors and multi-kinase inhibitors targeting 
AXL are already under development for treatment of 
several cancers [10]. For example, SKI606 (Bosutinib), 
a multi-kinase inhibitor targeting AXL, has been shown 
to reduce AXL-specific invasiveness in hepatocellular 
carcinoma cells and is in Phase 1 and 2 clinical trials 
for metastatic breast cancer [10, 51]. Additionally, R428 
(BGB324), a small molecule inhibitor of AXL, used in our 
in vitro experiments, is currently in clinical trials in acute 
myeloid leukemia and in non-small cell lung cancer. AXL 
inhibition via soluble AXL receptors in vivo has also been 
shown to reduce ovarian cancer metastasis in mice with 
established disease by 63% [24].
There has yet to be any study to target AXL 
in advanced EC. Thus, our findings may serve as a 
foundation for more studies on AXL in EC since AXL 
expression positively correlates with mesenchymal 
markers, increased metastasis, and drug resistance in 
various solid tumors [10, 32, 52-57]. Thus, these results 
may enable targeting AXL not only for invasion, but also 
for drug resistance and other associated issues in EC.
In summary, we demonstrate that genetic inhibition 
of AXL via shRNA is sufficient to significantly reduce EC 
metastatic progression and highlight clinical implications 
of AXL therapy for treatment of advanced or recurrent 
EC, against which current treatments can be significantly 
improved.
MATERIALS AND METHODS
Human Tissue Microarrays and 
Immunohistochemical Analysis
Commercial endometrial human tissue microarrays 
(TMAs) were obtained from US Biomax (Rockville, 
MD). Additionally, a tissue microarray containing sample 
cores from 10 patients with uterine papillary serous 
carcinoma who had undergone surgery at the University 
of Chicago between 1998 and 2007 was obtained from 
Ernst Lengyel (University of Chicago, IL) [58]. Another 
tissue microarray with corresponding survival data 
was constructed from patients treated at Washington 
University, under IRB approval. IHC was performed 
according to standard protocols. Briefly, slides were 
deparaffinized with xylene, rehydrated according to 
standard immunohistochemical methods, and stained with 
either anti-AXL primary antibody (R&D Systems, AF154; 
1:200) or no primary (negative controls). Slides were 
stained using the VECTASTAIN ABC system (Vector 
Laboratories, Burlingame, CA) and DAB Substrate Kit for 
Peroxidase (Vector Laboratories) and counterstained with 
hematoxylin. For the US Biomax and U of Chicago TMAs, 
tumor cell expression of membranous AXL was scored 
semiquantitatively according to the percentage of cells 
positive for AXL expression (0 for 0%, 1 for 1-19%, 2 for 
20-59%, and 3 for > 60%). For the Washington University 
TMA, AXL expression was recorded as a continuous 
variable. Data from this TMA was incorporated into Table 
1  according to the same scoring system (0 for 0%, 1 for 
1-19%, 2 for 20-59%, and 3 for > 60%). For the survival 
curve, IHC scores, 5–10% for low and 60–100% for 
high, was found to show the greatest survival difference 
between groups. Samples included various histologies 
including serous, mixed types, and endometrioid. Survival 
intervals were calculated from the date of surgery to death, 
or censored at the last date of visit.
Cell lines
Endometrial ARK1 cells were provided by Shi-
Wen Jiang (Mercer University School of Medicine, 
Savannah, GA, USA). Hec50a cells were a generous 
gift from Kimberly Leslie (University of Iowa Carver 
College of Medicine, Iowa City, IA, USA). AN3CA 
and KLE were obtained from American Type Culture 
Collection (Rockville, MD, USA), and Ishikawa cells 
were provided by Stuart Adler (Washington University 
School of Medicine, St. Louis, MO, USA). All cell lines 
were maintained in DMEM (Sigma, St. Louis, MO) 
supplemented with 10% heat inactivated FBS (Sigma, 
St. Louis, MO) and 1% penicillin and streptomycin 
(Invitrogen, Carlsbad, CA) at 37°C in a 5% CO2 incubator.
shRNA constructs and lentivirus transduction
ARK1 and Hec50a were transduced with 
lentivirus carrying either oligos encoding an AXL 
shRNA or a scrambled sequence (shSCRM). shAXL 
oligos were synthesized as previously described 
5’-GATTTGGAGAACACACTGA-3’ [37]. A scrambled 
sequence was used as a non-targeting shRNA control 
5’-AATTGTACTACACAAAAGTAC-3’. Oligos were 
cloned into the pSiren RetroQ (BD Bioscience) vector 
and infected ARK1 and Hec50a cells, which were then 
selected in puromycin (Sigma). For in vivo luciferase 
studies, ARK1 cells were transduced with retrovirus 
particles encoding for the expression of firefly luciferase 
gene (FLuc).
RNA interference
Human AXL siRNA (ON-TARGETplus SMART 
pool #L-003104-00-0005) and siControl (ON-
TARGETplus Non-targeting pool #D-001810-10-05) 
were from Dharmacon (Lafayette, CO). One day prior to 
transfection, ARK1 cells were plated in a 60 mm dish at 
50% confluence in DMEM medium supplemented with 
10% FBS without antibiotics. Cells were transfected with 
10 nM siRNAs using DharmaFECT 3 transfection reagent 
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(T-2003-02) according to the manufacturer’s instructions. 
Two days following transfection, ARK1 cells were plated 
into a 96-well plate for proliferation assays and harvested 
for western blot analysis of AXL expression at 24, 48, 72, 
and 96 hrs. Invasion and migration assays were also plated 
48 hours following siRNA transfection.
Proliferation assays
Cells were plated at densities of 4,000 cells per well 
into four 96-well plates in normal medium. Proliferation 
was measured at 24, 48, 72, and 96 hours using an 
2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-
5-carboxanilide inner salt (XTT)-based assay (Roche 
Molecular Biochemicals) as previously described [59]. Each 
experiment was done in triplicate and repeated three times.
Transwell invasion and migration assays
Matrigel invasion assays were performed according 
to the manufacturer’s protocol (Corning). Briefly, cells 
were serum starved for 24 hours and plated onto matrigel 
coated boyden chambers. Invasion assays were stained and 
analyzed after 16-48 hours. Migration assays were performed 
in a similar fashion, in uncoated Boyden chambers. Invaded 
cells were quantified by counting the number of invading 
cells per high-powered field. After 48 hours, invading cells 
on the bottom side of the membranes were fixed, stained, 
and counted in four different fields at 20X magnification. 
Migration of siRNA-treated ARK1 cells was counted at 10X 
magnification due to the distribution pattern of the migrated 
cells. The experiments were performed in triplicate wells and 
repeated at least three times.
For R428 invasion, ARK1 shSCRM and shAXL 
cells were serum-starved overnight and then treated with 
either serum-free media or 10 μM R428 (Selleckchem) for 
4 hours before plating into Matrigel chambers. Invading 
cells were fixed and stained after 48 hours.
Western blot analysis
Protein lysates were prepared from cultured 
cells or frozen tumors using a 9M Urea, 0.075 M Tris 
buffer (pH 7.6) and quantified using the Bradford assay. 
50-100μg of protein was subjected to reducing SDS/PAGE 
by standard methods. Western blots were incubated with 
primary antibodies against AXL (R&D Systems), P-AXL 
(Cell Signaling), GAS-6 (R&D), AKT (Cell Signaling), 
and phospho-AKT (Cell Signaling) as needed. To confirm 
equal protein loading, blots were probed with antibodies 
specific for β-actin (Sigma Aldrich), HSP70 (Thermo 
Fisher), or Vinculin (BD Pharmingen).
Zymogram
Hec50a shSCRM/AXL cells were starved in serum 
free media for 48 hours and 25,000 cells were plated 
into a 96 well plate in SF media. Conditioned media was 
collected 24 hours later. Equal volumes of conditioned 
media were run under non-reducing conditions on 10% 
gelatin zymogram gels (BioRad). After electrophoresis, 
gels were incubated in zymogram renature buffer 
(BioRad) for 30 min at RT and then incubated overnight 
in zymogram development buffer (BioRad) at 37°C. Gels 
were stained for 30 min with Coomassie Brilliant Blue 
R250 and destained in 40% methanol and 10% glacial 
acetic acid.
RT-PCR
The RNeasy mini kit (Qiagen) was used to isolate 
RNA, 1 µg of which was used to make cDNA using 
the Quantitect Reverse Transcription kit (Qiagen) 
according to the manufacturer’s protocol. RT-PCR was 
performed on 30 ng of cDNA using Fast SYBR Green 
Master Mix and the 7500 Fast Real-time PCR System 
(Applied Biosystems). Sequences of primers used were: 
18S Fwd: 5-GCCCGAAGCGTTTACTTTGA-3 Rev: 
5-TCCATTATTCCTAGCTGCGGTATC-3 [60]; AXL 
Fwd: 5-GTGGGCAACCCAGGGAATATC-3 Rev: 
5-GTACTGTCCCGTGTCGGAAAG-3 [60]; MMP-1: 
Fwd: 5-ACACATCTGACCTACAGGATTGA-3 Rev: 
5-GTGTGACATTACTCCAGAGTTGG-3 [24]; MMP-
2 Fwd: 5-GCCCCAGACAGGTGATCTTG-3 Rev: 
5-GCTTGCGAGGGAAGAAGTTGT-3 [24]; MMP-
3 Fwd: 5-TTCCTGGCATCCCGAAGTGG-3 Rev: 
5-ACAGCCTGGAGAATGTGAGTGG-3 [61]; MMP-
9 FWD 5-GGGACGCAGACATCGTCATC-3 REV: 
5-TCGTCATCGTCGAAATGGGC-3 [24]; uPA Fwd: 
5-AGGGCAGCACTGTGAAATAGATAAGT-3 Rev: 
5-CATGGTACGTTTGCTGAAGGA-3 [62]. Fold change 
in mRNA expression was calculated by the delta-delta 
CT method. Expression of corresponding genes was 
normalized to that of the housekeeping gene 18S. Each 
value was measured in triplicate, and the experiment was 
repeated at least twice.
Orthotopic Model of Uterine Cancer
All procedures involving animals and their care 
were performed in accordance with the guidelines of the 
American Association for Accreditation for Laboratory 
Animal Care and the U.S. Public Health Service Policy 
on Humane Care and Use of Laboratory Animals. All 
animal studies were also approved and supervised by the 
Washington University Institutional Animal Care and Use 
Committee in accordance with the Animal Welfare Act, 
the Guide for the Care and Use of Laboratory Animals, 
and NIH guidelines.
ARK1 cells were transduced with retrovirus 
particles encoding firefly luciferase, then transfected with 
shSCRM and shAXL as described above. shSCRM and 
shAXL ARK1 cells (10x106 cells in 0.5 ml of PBS) were 
injected intraperitoneally (i.p.) into female 6-to-8-week 
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old (n=9) (NOD) SCID (Jackson Laboratory). Mice 
were monitored for adverse events until sacrifice. 
Approximately 35 days after injection, mice was 
subjected to bioluminescence imaging to monitor 
tumor growth as previously described [63]. Briefly, 
living mice were injected with 150 mg/mL D-luciferin 
(Gold Biotech) in PBS and imaged with a charge-
coupled device (CCD) camera-based bioluminescence 
imaging system (IVIS50; Perkin-Elmer, Hopkinton, 
MA; exposure time 10s - 1minute, binning 8, field of 
view 12, f/stop 1, open filter). Bioluminescence signal 
was displayed as photons/sec/cm2/sr. At the completion 
of each experiment (60 days), mice were sacrificed, and 
aggregate tumor weight, location, and number of tumor 
nodules were recorded for each group. Tumor samples 
were fixed in formalin and embedded in paraffin for 
further analysis.
Immunohistochemical analysis of Ki-67 
expression in mouse xenografts
Mouse xenograft tumors were placed in fresh 
formalin for a minimum of 24 hours before processing 
for paraffin embedding. Sections were cut at 5 μm and 
mounted on glass slides. Slides were deparaffinized and 
hydrated in Xylene, gradually diluted in ethanol and water 
followed by antigen retrieval in Sodium Citrate at pH 6. 
Slides were probed with 1:2000 diluted Ki67 (AbCam) 
at 4C overnight, then washed and incubated with HRP 
conjugated secondary antibody. Antibody complexes were 
detected with 3,3’-diaminobenzidine and counter stained 
with Mayer’s Hematoxylin.
Statistical Analyses
Prism software (GraphPad) was used for statistical 
analyses. Two-tailed unpaired Student’s t tests were 
performed to analyze statistical differences between 
groups. P values < 0.05 were considered statistically 
significant.
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